GeneDx Holdings (WGS) EBITDA (2020 - 2026)

GeneDx Holdings (WGS) has 7 years of EBITDA data on file, last reported at -$63.6 million in Q1 2026.

• EBITDA for Q1 2026 came in at -$63.6 million, down 884.96% year-over-year; the trailing twelve-month figure through Mar 2026 was -$78.0 million (down 105.55% YoY), and the FY2025 annual result was -$20.9 million, up 59.69% from the prior year.
• EBITDA eased to -$63.6 million in Q1 2026 per WGS's latest filing, from -$17.7 million in the prior quarter.
• Over five years, EBITDA peaked at $10.7 million in Q2 2025 and troughed at -$308.8 million in Q4 2022.
• A 5-year average of -$50.6 million and a median of -$29.0 million in 2024 frame the typical range for EBITDA.
• The sharpest annual moves came in 2025 and 2026: EBITDA surged 136.95% in 2025, then sank 884.96% in 2026.
• A 5-year view of EBITDA shows it stood at -$308.8 million in 2022, then soared by 91.79% to -$25.3 million in 2023, then soared by 121.11% to $5.4 million in 2024, then slumped by 431.44% to -$17.7 million in 2025, then sank by 258.5% to -$63.6 million in 2026.
• Business Quant data shows WGS's EBITDA at -$63.6 million in Q1 2026, -$17.7 million in Q4 2025, and -$7.4 million in Q3 2025.